This protocol addresses acute respiratory failure (ARF) arising in the context of COVID-19 (SARS-CoV-2 infection). A proportion of patients with COVID-19 develop ARF and acute respiratory distress syndrome (ARDS), with risk influenced by patient age, comorbidities, immune status, and viral genotype, among other factors.
Management centres on ventilatory strategies aligned with ARF and ARDS principles. For non-intubated patients, specific positioning strategies are incorporated into the care pathway. Pharmacological therapy is guided by COVID-19-specific clinical guidelines.
A certain proportion of patients with COVID-19 develop ARF and ARDS depending on patient age, comorbidities, immune status, and SARS-CoV-2 virus genotype among other factors.
In patients with COVID-19, ventilatory management is essentially the same as for ARF and ARDS, but awake prone positioning may be considered.
In addition to standard ventilatory management, the benefits of awake prone positioning for non-intubated patients have been posited and examined.
Pharmacological therapies, including corticosteroids, should be administered according to the guidelines and statements specific to COVID-19.
DOI: 10.1186/s40560-023-00658-3
View source ↗